For decades, the idea that the human brain might naturally produce the psychedelic compound DMT has attracted considerable ...
The drug – called SPL026 – was originally developed by UK firm Small Pharma, which was acquired by Canadian firm Cybin in ...
Clinical Trials Arena on MSN
Helus’ DMT psychedelic touts antidepressant potential in Phase IIa study
These results come as the race to commercialise the first FDA-approved psychedelic continues.
The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...
A viral park warning revived myths about psychedelic toads, but scientists say licking them brings danger, conservation risks ...
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant ...
The Put Option Agreement grants PsyLabs the right, but not the obligation, to require the Company to make a further equity investment in PsyLabs by way of a share-for-share exchange at arm’s length ...
Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies ...
A new study finds no evidence of naturally occurring DMT or its storage in the serotonin neurons of the rat brain.
New findings from Karolinska Institutet reveal how the gene HNRNPU coordinates several fundamental molecular processes during ...
Searching for blockbuster drugs and wonder materials is an arduous task for chemists. To make promising compounds, they must trawl through millions of known chemical reactions, with hundreds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results